JP2010540654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540654A5 JP2010540654A5 JP2010528129A JP2010528129A JP2010540654A5 JP 2010540654 A5 JP2010540654 A5 JP 2010540654A5 JP 2010528129 A JP2010528129 A JP 2010528129A JP 2010528129 A JP2010528129 A JP 2010528129A JP 2010540654 A5 JP2010540654 A5 JP 2010540654A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- compstatin analog
- composition
- seq
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 216
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims description 169
- 239000007788 liquid Substances 0.000 claims description 156
- 238000000034 method Methods 0.000 claims description 47
- 230000007423 decrease Effects 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 229940124073 Complement inhibitor Drugs 0.000 claims description 7
- 239000004074 complement inhibitor Substances 0.000 claims description 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 150000005846 sugar alcohols Chemical class 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 229960005475 antiinfective agent Drugs 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 239000000730 antalgic agent Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 8
- 108010027437 compstatin Proteins 0.000 description 7
- 108010069514 Cyclic Peptides Proteins 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 4
- -1 antibody Chemical class 0.000 description 4
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 3
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97691907P | 2007-10-02 | 2007-10-02 | |
| US2646008P | 2008-02-05 | 2008-02-05 | |
| PCT/US2008/078593 WO2009046198A2 (en) | 2007-10-02 | 2008-10-02 | Sustained delivery of compstatin analogs from gels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540654A JP2010540654A (ja) | 2010-12-24 |
| JP2010540654A5 true JP2010540654A5 (enExample) | 2011-10-27 |
Family
ID=40526950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528129A Pending JP2010540654A (ja) | 2007-10-02 | 2008-10-02 | ゲルからのコンプスタチンアナログの持続的送達 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110182877A1 (enExample) |
| EP (1) | EP2207530A4 (enExample) |
| JP (1) | JP2010540654A (enExample) |
| KR (2) | KR20150080007A (enExample) |
| CN (1) | CN101854916A (enExample) |
| AU (1) | AU2008308657A1 (enExample) |
| BR (1) | BRPI0817524A2 (enExample) |
| CA (1) | CA2701470A1 (enExample) |
| MX (1) | MX2010003630A (enExample) |
| RU (1) | RU2505311C2 (enExample) |
| WO (1) | WO2009046198A2 (enExample) |
| ZA (1) | ZA201002365B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US20110092446A1 (en) * | 2007-07-20 | 2011-04-21 | Cedric Francois | Compositions and methods for treatment of trauma |
| WO2009121065A2 (en) * | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| TWI492769B (zh) | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| US9107822B2 (en) | 2010-09-03 | 2015-08-18 | Santen Sas | Water-in oil type emulsion for treating a disease of the eye |
| NZ607103A (en) | 2010-09-03 | 2015-09-25 | Santen Sas | A water-in-oil type emulsion for treating a disease of the eye |
| EP2425814B1 (en) | 2010-09-03 | 2013-06-19 | Novagali Pharma S.A. | A water-in-oil type emulsion for treating a disease of the eye |
| RU2653439C9 (ru) | 2011-05-11 | 2018-10-16 | Апеллис Фармасьютикалс, Инк. | Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение |
| CA2840270C (en) * | 2011-06-22 | 2023-09-26 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| WO2014028861A1 (en) * | 2012-08-17 | 2014-02-20 | Apellis Pharmaceuticals, Inc. | Detection of high risk drusen |
| US10035822B2 (en) | 2012-11-15 | 2018-07-31 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| US9940683B2 (en) | 2013-07-31 | 2018-04-10 | Elwha Llc | Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period |
| US20150039337A1 (en) * | 2013-07-31 | 2015-02-05 | Elwha Llc | Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period |
| EP2918262B1 (en) | 2014-03-10 | 2023-08-09 | PLS-Design GmbH | Induction of antigen-specific tolerance by peripheral phagocytosis |
| BR122021025449B1 (pt) | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Composto, polipeptídeo e composição compreendendo o mesmo |
| US20180228811A1 (en) * | 2014-12-12 | 2018-08-16 | The Schepens Eye Research Institute, Inc. | Gdnf induction for the treatment of retinal disorders |
| SMT202100688T1 (it) | 2015-01-28 | 2022-01-10 | Ra Pharmaceuticals Inc | Modulatori di attività del complemento |
| EP3095440B1 (en) | 2015-05-19 | 2020-01-15 | PLS-Design GmbH | Antigen-specific immunotherapy using tolerizing liposomes |
| KR20180090785A (ko) | 2015-10-07 | 2018-08-13 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 |
| KR20260070290A (ko) | 2015-12-16 | 2026-05-18 | 유씨비 홀딩스 인코포레이티드 | 보체 활성의 조절인자 |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| RU2661621C2 (ru) * | 2016-12-19 | 2018-07-17 | Александр Николаевич Епихин | Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций |
| BR112019020955A2 (pt) | 2017-04-07 | 2020-05-05 | Apellis Pharmaceuticals, Inc. | regimes de dosagem e composições e métodos relacionados |
| JP2021507884A (ja) | 2017-12-15 | 2021-02-25 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| ES2973767T3 (es) | 2019-06-04 | 2024-06-24 | Ra Pharmaceuticals Inc | Tratamiento de enfermedades inflamatorias con inhibidores del complemento |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7488590B2 (en) * | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7989589B2 (en) * | 2002-09-20 | 2011-08-02 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved activity |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| CN101325963B (zh) * | 2005-10-08 | 2016-01-27 | 博泰迪亚制药公司 | 用于眼部病症的补体抑制素和其类似物 |
| ES2390828T3 (es) * | 2005-11-28 | 2012-11-16 | The Trustees Of The University Of Pennsylvania | Análogos potentes de la compstatina |
| JP2009521506A (ja) * | 2005-12-22 | 2009-06-04 | アルコン リサーチ， リミテッド | 補体因子ｈの危険である改変体をもつ患者における年齢による斑状変性の予防および処置のためのｃ３コンバターゼインヒビター |
| US20070196367A1 (en) * | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| EP2148691B1 (en) * | 2007-02-05 | 2015-05-20 | Apellis Pharmaceuticals, Inc. | Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system |
-
2008
- 2008-10-02 CA CA2701470A patent/CA2701470A1/en not_active Abandoned
- 2008-10-02 JP JP2010528129A patent/JP2010540654A/ja active Pending
- 2008-10-02 WO PCT/US2008/078593 patent/WO2009046198A2/en not_active Ceased
- 2008-10-02 KR KR1020157016589A patent/KR20150080007A/ko not_active Ceased
- 2008-10-02 AU AU2008308657A patent/AU2008308657A1/en not_active Abandoned
- 2008-10-02 EP EP08836209.0A patent/EP2207530A4/en not_active Withdrawn
- 2008-10-02 US US12/681,392 patent/US20110182877A1/en not_active Abandoned
- 2008-10-02 RU RU2010113513/15A patent/RU2505311C2/ru not_active IP Right Cessation
- 2008-10-02 CN CN200880115155A patent/CN101854916A/zh active Pending
- 2008-10-02 MX MX2010003630A patent/MX2010003630A/es unknown
- 2008-10-02 KR KR1020107008703A patent/KR20100094453A/ko not_active Ceased
- 2008-10-02 BR BRPI0817524A patent/BRPI0817524A2/pt not_active IP Right Cessation
-
2010
- 2010-04-01 ZA ZA2010/02365A patent/ZA201002365B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220025028A1 (en) | Methods of Treating or Preventing Periodontitis and Diseases Associated with Periodontitis | |
| US10945962B2 (en) | Controlled-release peptide compositions and uses thereof | |
| CN101296704B (zh) | 用于减少cd36表达的方法 | |
| US11241487B2 (en) | Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders | |
| US10363282B2 (en) | Analogs of C5a and methods of using same | |
| RU2010113513A (ru) | Пролонгированная доставка аналогов компстатина из гелей | |
| US10800812B2 (en) | Compstatin analogs with increased solubility and improved pharmacokinetic properties | |
| US20190117741A1 (en) | Compositions and methods for treating and preventing lung disease | |
| US20200172587A1 (en) | Hydrochloride salts of c5a receptor agonist peptides | |
| CN118076372A (zh) | 治疗和预防肺病的组合物和方法 | |
| WO2025123051A1 (en) | Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain | |
| HK40074502A (en) | Compstatin analogs with increased solubility and improved pharmacokinetic properties | |
| JP2025503607A5 (enExample) | ||
| HK40030234B (en) | Compstatin analogs with increased solubility and improved pharmacokinetic properties | |
| HK1212718B (en) | Methods for reducing cd36 expression | |
| NZ621790B2 (en) | Cardiovascular therapeutics |